ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).

Samuel J. Klempner,Liangliang Zhang,Ryon Graf,Russell Madison,Jeremy Snider,Cheryl D. Cho-Phan,Emily Castellanos,Gerald Li,Halla Nimeiri,Garrett M. Frampton,Geoffrey R. Oxnard,Jeffrey Venstrom,Kimberly McGregor,Alexa Betzig Schrock

ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).

2021

Samuel J. Klempner
Liangliang Zhang
Ryon Graf
Russell Madison
Jeremy Snider
Cheryl D. Cho-Phan
Emily Castellanos
Gerald Li
Halla Nimeiri
Garrett M. Frampton
Geoffrey R. Oxnard
Jeffrey Venstrom
Kimberly McGregor
Alexa Betzig Schrock

4045Background: HER2 (ERBB2) overexpression or amplification (amp) are biomarkers for approved anti-HER2 therapies. ERBB2amp may be a superior predictor of anti-HER2 therapy outcome compared to IHC...

Keywords:

Immunohistochemistry
Internal medicine
Medicine
anti her2
Oncology
Biomarker (medicine)
gastroesophageal adenocarcinoma
Therapy Outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations